Subcutaneous daratumumab offers shorter clinic visits and high tolerability for patients with multiple myeloma, says ...

Cancer survivors, particularly men, in physically demanding jobs often face pressure to keep working during treatment, says ...

For patients with HR-positive breast cancer, adverse effects vary by CDK4/6 inhibitor, says Courtney Moore, APRN, FNP-C, OCN.

Nurses should be familiar with PET scan protocol and what to ask patients with lung and bone cancers before administering ...

Panelists discuss that shifting talquetamab dosing from weekly to every 2 weeks improves response durability and patient ...

Panelists highlight advances in myeloma treatment, focusing on innovative T cell therapies like CAR T and T-cell engagers, ...

C, CNS, explained that understanding a patient’s emotional needs can help educate them on treatment adherence.

Panelists discuss how dose modifications for ALK inhibitors can significantly improve quality-of-life issues such as brain ...

Hope S. Rugo, MD, FASCO, outlined the top considerations for nurses managing toxicities related to PI3K and AKT inhibitors in ...

Panelists discuss City of Hope’s collaborative partnership with community physicians, emphasizing expert evaluation at ...

Panelists emphasize the importance of multidisciplinary collaboration, patient education, and advocacy in managing multiple ...

The FDA has granted accelerated approval to dordaviprone for use in adult and pediatric patients with H3 K27M-mutated diffuse midline glioma.